Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer

Immunotherapy

Volumn 7, Issue 6, 2015, Pages 631-640

  Phaeton R ^a   Gutierrez, J ^a   Jiang, Z ^a   Karabakhtsian, R G ^a   Albanese, J ^a   Sunkara, J ^a   Fisher, D R ^b   Goldberg, G L ^a   Dadachova, E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Dade Moeller Associates   (United States)

Author keywords

188Rhenium; apoptosis; complement cytotoxicity; E6 and E7 oncoproteins; HPV16 positive cervical cancer; p53 expression; radioimmunotherapy; retinoblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C1P5 RE 188; PROTEIN E6; PROTEIN E7; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG; CANCER ANTIBODY; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODIES, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RADIOIMMUNOTHERAPY; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84937719366     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.18     Document Type: Article

References (29)

1. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer Carcinogenicity of human papillomaviruses. Lancet Oncol. 6, 204-210 (2005).
2. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanisms of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 5(4), e100397 (2009).
3. Ho L, Chan SY, Burk RD et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J. Virol. 67, 6413-6423 (1993).
4. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92, 690-698 (2000).
5. Martin AG. Molecular biology of cervical cancer. Clin. Transl. Oncol. 9, 347-354 (2007).
6. Dadachova E, Wang XG, Casadevall A. Targeting the virus with radioimmunotherapy in virus-assoicated cancer. Cancer Biother. Radiopharm. 7, 595-597 (2007).
7. Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. The influence of proteasome inhibitor MG132, external radiation n and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 116(S4), 1067-1074 (2010).
8. Phaeton R, Harris M, Jiang Z et al. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6. Cancer Biol. Ther. 10, 1041-1047 (2010).
9. Cai Q, Lv L, Shao Q, Li X, Dian A. Human papillomavirus early proteins and apoptosis. Arch. Gynecol. Obstet. 287(3), 541-548 (2013).
10. Wang XG, Revskaya E, Bryan RA et al. Treating cancer as an infectious disease-viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS ONE 2(10), e1114 (2007).
11. Dadachova E, Mirzadeh S. The role of tin in the direct labelling of proteins with Rhenium-188. Nucl. Med. Biol. 24, 605-608 (1997).
12. Miller WH, Hartmann-Siantar C, Fisher DR et al. Evaluation of beta absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu and radionuclides. Cancer Biother. & Radiopharm. 20(4), 436-449 (2005).
13. Eckerman KF, Endo A. MIRD Radionuclide Data and Decay Schemes, 2nd Edition. Society of Nuclear Medicine, Reston, VA, USA (2008).
14. Harrison P, Briggs C, Machin SJ. Platelet counting. Methods Mol. Biol. 272, 29-46 (2004).
15. Bryan RA, Jiang Z, Jandl T et al. Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev. Anticancer Ther. 14, 1243-1249 (2014).
16. Pickhard A, Piontek G, Seidl C et al. Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. Nucl. Med. Biol. 41, 68-76 (2014).
17. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13, 954-966 (2008).
18. Macklis RM. How and why does radioimmunotherapy work? Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1269-1271 (2004).
19. Morgan BP. Regulation of the complement membrane attack pathway. Crit. Rev. Immunol. 19, 173-198 (1999).
20. Jandl T, Revskaya E, Jiang Z, Bryan RA, Casadevall A, Dadachova E. Unlabeled antibody to melanin contributes to the radioimmunotherapeutic efficacy of metastatic melanoma through complement-dependent cytotoxicity. Immunotherapy 5(4), 1-7 (2013).
21. Simpson K, Jones A, Norman S, Holmes CH. Expression of complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD 59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am. J. Pathol. 151, 1455-1467 (1997).
22. Liu L, Li W, Li Z, Kirschfink M. Sublytic complement protects prostate cancer cells from tumour necrosis factor-?-induced cell death. Clin. Exp. Immunol. 169, 100-108 (2012).
23. Gelderman KA, Block VT, Flueren GJ, Gorter A. The inhibitory effect of CD46, CD55 and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monocolonal antibodies. Lab Invest. 82(4), 483-493 (2002).
24. Loddenkemper C, Hoffmann C, Stanke J et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cancer. Cancer Sci. 100, 1112-1117 (2009).
25. Wu MY, Kuo T, Ho H. Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3+ T lymphocytes in cervical cancer. J. Formosan Med. Association 110, 580-586 (2010).
26. de Geus B1, van den Enden M, Coolen C, Rozing J. Localization and phenotype of CD3 associated gamma/delta receptor expressing intestinal intraepithelial lymphocytes. Thymus 14, 31-41 (1989).
27. Adurthi S, Krishna S, Mukherjee G, Bafna UD, Devi U, Jayshree RS. Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepthelial neoplasia and squamous cell carcinoma. Amer. J. Reproductive Immunol. 60, 55-65 (2008).
28. Harris M, Wang XG, Jiang Z et al. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br. J. Cancer 108(4), 859-865 (2013).
29. Taghian AG, Abi-Raad R, Asaad SI et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancer cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23, 1951-1961 (2005).